Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

Transgenomic and Fiuotecnica Renew Cardiovascular Disease Gene Panel Agreement

  • Transgenomic renewed a collaboration with Fiuotecnica  to produce and market a genetic panel assay to predict the risk of cardiovascular disease and heart attacks using Transgenomic's WAVE® System.

    Transgenomic will supply its WAVE System technology and related reagents to Fiuotecnica. Upon completion of the assay development, Fiuotecnica will retain rights to market the cardiovascular panel in Italy, while Transgenomic will obtain rights to market the assay in the rest of the world.

    "Fiuotecnica has evaluated other platforms, but we believe that Transgenomic's unique technology platforms, including the WAVE System for DHPLC analysis and Surveyor Nuclease, provide the highest sensitivity for mutation detection," states Antonio Mele, CEO of Fiuotecnica.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »